Introduction
Inherited thrombophilia is a group of disorders characterized by hypercoagulable states that can lead to thrombotic events. Genetic predisposition to thromboembolism may be suspected in patients who have thrombosis at a young age, have recurrent thrombosis, or have thrombosis in an unusual site. A genetic predisposition can be also suspected in individuals who have a strong family history of thrombotic events. These episodes may occur in the absence of known causes or can be associated with other prothrombotic conditions such as pregnancy, immobilization, postoperative state, advancing age, estrogen therapy, malignancy, diabetes, or presence of antiphospholipid syndrome. 1 Congenital disorders predisposing for thrombosis are not only antithrombin, protein C, Factor V Leiden (FVL) and G20210 prothrombin (FII G20210A) mutations are risk factors for thromboembolism. In Europe, FVL is more prevalent in the north (7%) than in the south (3%), whereas FII G20210A is more common in the south (3% to 7%) than in the north (2% to 5%). In Italy, the prevalence is 2% to 3% for both. The aim of this study was to assess if these polymorphisms could be more frequent in the south than in the rest of Italy. In 105 blood donors in southern Italy, the prevalence of FVL and FIIG20210A was 9.5% and 5.7%, respectively. These prevalence data are higher when compared with published data. The results of this study are as high as those observed in Greece and the Middle East. The diffusion of FVL and FII G20210A in the Mediterranean, consequent to Phoenician and Greek colonization, could be a reason for the high prevalence observed.
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Brief Reports
The prevalence of FVL within Europe varies widely, with a peak carrier frequency of 15% found in Greeks and Greek-Cypriots. These data could suggest that Greece was the origin of FVL mutation, and the invading armies of Alexander the Great spread the mutation throughout Europe and north India, but the high prevalence of FVL in Scandinavia cannot be explained with this model. Other studies that were extended to various European populations have confirmed the association of the prevalence of prothrombotic mutations with geographic location: the percentage of FII G2010A in southern Europe/ Middle East (3% to 7%) is higher than in northern Europe (2% to 5%); however, the prevalence of FVL in northern Europe (7%) is higher than in southern Europe (3%), especially in Sweden. 9, 10 
Study
The aim of the present study was to investigate the prevalence of FVL and prothrombin G20210A gene variant in a group of blood donors in a hospital. In the past years, we observed higher prevalence of genetic thrombophilia in our patients than before. We investigated a group of 3195 Caucasians from the same geographic area of south Italy, referred to our centre, between January 2000 and January 2007. This group included patients with arterial or venous thromboembolism, healthy subjects with familial history of vascular disease, and healthy women who underwent screening for thrombophilia before taking oral contraceptives. The observed prevalence was 11.1% (355/3195) for FVL and 11.4% (364/3195) for FII G20210A. The recent studies regarding the prevalence of the carrier of FVL and FII G20210A variants in Italy, which is 2% to 3% for both FVL and FII G20210A in north and central Italy, 6, 9, 10 made us assess if these disorders might be more frequent in healthy Calabrian population than in the rest of Italy.
Materials and Methods
This investigation was carried out in 105 unselected subjects (69 males, 36 females; median age, 43 years) recruited from blood donors of Service of Transfusional Medicine of Reggio Calabria (Italy) from January 2005 to December 2006. All the subjects studied were Caucasians, in good health, without a history of vascular disease, and born in Calabria, a region in south Italy. To avoid selection of the subjects, we focused our attention only on the individuals without considering whether or not the donors were members of a family with history of thromboembolic events. After obtaining informed consent, the investigation on the FVL and FII G20210A mutations was made by venous blood samples, which were collected into vacutainer tubes containing ethylenediaminetetraacetic acid. The assays were based on the reverse-hybridization principle and included 3 successive steps: extraction of genomic DNA from peripheral blood leukocytes, in vitro amplification of gene sequences, and hybridization of the amplification products with allele-specific oligonucleotide probes (ViennaLab, Vienna, Austria).
Results
Among the 105 donors studied, 10 subjects were found heterozygous for FVL, 6 heterozygous for FII G20210A mutation, no one homozygous for FVL and FII G20210A, and no carriers for both mutations. The prevalence of FVL in the subjects was found to be 9.5% (10/105) (allele frequency, 0.048), whereas the prevalence of prothrombin G20210A mutation was 5.7% (6/105) (allele frequency, 0.029). These data differ from the results reported in the literature regarding the prevalence of the FVL and FII G20210A variants in healthy Italians. The results are shown in Table 1 .
Discussion
The available literature concerning the data about the prevalence of the carrier of the FVL and FII G20210A variants is associated with geographical location. The prothrombotic mutations are extremely rare among non-Caucasians (African Blacks, Chinese, Japanese, native Northern and Southern Americans, or Greenland Inuit).
Among the geographic distribution of FVL, the peak carrier frequency with a remarkably high prevalence was found in Israeli Arabs (37.1%) 11 and in the Middle East and Cyprus (14.2% and 13.3%, respectively). 12, 13 It was also found in Azerbaijan, Dagestan, and north India. Rees 9 found variability in the prevalence in Europe. Higher percentages were found in Greeks, Greek-Cypriots (15%), and in north Europe, especially in southern Sweden (10.8%). The situation in the American continent and the Australian continent reflects the recent large immigration from all over the world of people with prothrombotic variant frequencies that represent a European origin; however, they are absent in indigenous populations. Rosendaal et al 10 combined data on the prevalence of the carrier of the prothrombin G20210A variant from 11 centers in 9 countries. They observed a clear relationship of the prevalence of FII G20210A with the geographic latitude in Europe and the Middle East. In the centers located north of 50°N (Manchester, Sheffield, Amsterdam, Leiden), the prevalence is 1.7%; in the centers located south of 50°N (Paris, Wien, Tel Aviv), the prevalence is 3%. Among individuals with African background, the prevalence of the FII G20210A carrier is 0.67%; among Native Americans and Asians, no carriers were detected. The mutation is also absent in Inuit from Greenland and in individuals from the Amazon region in Brazil. These combined data indicate that the mutation has a higher prevalence in southern Europe (3%) than in northern Europe (1.7%). Different studies based on investigations among various groups of individuals in different countries have shown that the prevalence of FII G20210A is 7.8% in the Greek-Cypriot population, 2.5% in Syria and Lebanon, and 2% in Jordan. 12, 14 In North Africa, the prevalence of FVL and FII G20210A might indicate a genetic drift from Middle East ancestors, especially in Tunisia (5.4% and 3.9%, respectively), where the frequencies are strikingly higher than in neighboring countries (Algeria, Morocco). 15, 16 This difference could be explained by the fact that Tunisia was invaded by Phoenicians, a population that originated from the Middle East (Syria and Lebanon).
The aim of the present study was to investigate the prevalence of FVL and prothrombin G20210A mutations among unselected healthy individuals living in a southern region of Italy. The purpose of our study was also to verify the hypothesis of a single origin of these prothrombotic variants in the Middle East about 20 000 to 30 000 years ago, which had been spreading to the Mediterranean area and the northeast of Europe with human migrations during the Neolithic times from 10 000 years ago. Until now, the precedent surveys have only provided FVL and FII G20210A prevalence among Italian Caucasians living in central or northern regions in the country. We think studies should consider the possibility of several differences between northern, central, and southern regions, and our opinion could be supported by the fact that there is higher Neolithic expansion in the south than in the north of Italy. 17 In conclusion, our study seems to contribute to the hypothesis of a single origin for FVL and FII G20210A mutations in the Middle East. The high prevalence in healthy individuals of southern Italian reported in our study could be the consequence of the Phoenicians and Greek colonization in these regions.
The limitation of this study could be the small number of individuals enrolled, but we think that the examination of a large uniform study group representative of all regions in south Italy could lead to analogous prevalence. If it is confirmed, the evidence of genetic differences between Italian regions should lead to further studies for the geographic risk identification and for the evaluation of the correct prophylaxis treatment in thrombophilic individuals who are exposed to acquired thrombotic risk factors such as surgery, trauma, prolonged immobilization in bed, pregnancy and puerperium, estrogen use, and cancer. 18 
